Recent insider selling of PROCEPT BioRobotics shares and lack of insider buying, along with not particularly high insider ownership, raises caution about the company. Consider the company's investment risks before purchasing.
PROCEPT BioRobotics has a conservative balance sheet and could probably eliminate its debt without much difficulty. Despite losing money over the last twelve months, the company's solid revenue growth may indicate a path to profitability.
Insider selling at PROCEPT BioRobotics' current share price levels doesn't imply major concern nor positivity. Lack of insider purchases in the past year and shares held by insiders, combined with past sales, call for careful investments due to potential company risks.
Stocks on IPO and during their first year will face extreme volatility. The stocks will requires many conditions, such as good management, good business plan and good luck, to ensure its survival. Investors, especially new ones, will need to pick them more carefully. Here is the result for last week IPO stocks. Did you got the right ones?
IPOs see strong demand as investors are seeking new companies that offer innovative products and services in wide ranging and diverse areas. A number of well received IPOs have enjoyed terrific returns which could be attributed to market exuberance over these new listings. This comes as no surprise as the US market is the mainstay of most global portfolios of investors and also home to multiple fast growing companies across various industries. With the market reaching new all time highs, concerns are increasing about new listings overheating. The newly listed companies also tend to be more volatile during their first few earnings seasons as market expectations will rest on if they could deliver the promised targets. Investors need to be aware that early institutional investors look to exit their holdings within a year or so while retail investors are buying in, which results in increased volatility. Investment decisions should always be guided by a fundamental analysis of the company and its valuation to ensure that investors are not taking unnecessary risks to their portfolios by jumping on this IPO bandwagon blindly. $Definitive Healthcare(DH.US)$ $DICE THERAPEUTICS, INC.(DICE.US)$ $Dutch Bros(BROS.US)$ $昂跑(ONON.US)$ $PROCEPT BioRobotics(PRCT.US)$ $Sportradar Group AG(SRAD.US)$ $Thoughtworks(TWKS.US)$ $Tyra Biosciences(TYRA.US)$
PROCEPT BioRobotics股票討論區
專欄Top upgrades and downgrades on 7/15: QCOM, DAL, CSCO, DRE and more
• $Allogene Therapeutics(ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX(CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX運輸(CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
•$德希尼布FMC(FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $諾福克南方(NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...
Last week (13 Sep to 17 Sep 2021) IPO result
Here is the result for last week IPO stocks. Did you got the right ones?
Strong Demand for IPOs
$Definitive Healthcare(DH.US)$
$DICE THERAPEUTICS, INC.(DICE.US)$
$Dutch Bros(BROS.US)$
$昂跑(ONON.US)$
$PROCEPT BioRobotics(PRCT.US)$
$Sportradar Group AG(SRAD.US)$
$Thoughtworks(TWKS.US)$
$Tyra Biosciences(TYRA.US)$
$120
lets do that by friday
$Sonnet BioTherapeutic(SONN.US)$
$Vinco Ventures(BBIG.US)$
$aTyr Pharma(LIFE.US)$
暫無評論